Gastrointestinal Cancers: Immediate Impact of 2016 ASCO Presentations on Clinical Practice

Introduction

In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores presentations concerning the sidedness of the primary tumor in metastatic colorectal cancer(mCRC) and the potential use of gemcitabine + capecitabine (GEMCAP) as adjuvant therapy in resected pancreatic cancer patients.

OncoPoll™ Methodology

  • Primary research phase involved a global survey to verified and validated medical oncologists and multi-disciplinary physicians with an identified clinical interest in GI cancers utilizing targeting parameters within the proprietary MDoutlook® global cancer treater panel
  • Timing: June 2016. Launched 3 days after close of 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL., June 3-7, 2016
  • Fielding to proprietary panel of cancer treaters, targeted by clinical interest.
  • Data capture via interactive web-based survey instrument, utilizing proven MDoutlook methodology and proprietary technology
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Reponses at data collection: 134
  • Responses are from 17 countries: Austria, Belgium, Brazil, Canada, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Slovakia, Spain, Sweden, Switzerland, United Kingdom and US

Geographic Distribution and Attendance of Respondents

OncoPoll_GI_Figure1

Primary Tumor Sidedness in mCRC:

Awareness & Importance of Abstracts #3504, 3405 and 3406

 OncoPoll_GI_Figure2

Key Conclusions

  • On a 0 – 5 scale of 0 = no awareness to 5 = very aware, clinicians have an above average awareness of ~3.3
    • No difference seen between US and ex-US respondents
    • Higher level of awareness was seen among the attendees compared to those who did not attend (not shown)
  • Clinical impact, also rated on a 0 – 5 scale of 0 = no impact at all to 5 = very important, oncologists see this new information as clinically meaningful, with average rating of ~3.3
    • Those outside of the US assign slightly more importance to this information
    • Only small differences in importance was seen between attendees and non-attendees (not shown)
    • Changes in treatment selections will primarily occur only for left-sided tumors, with a 38% increase in the use of FOLFOX or FOLFIRI + cetuximab, with a 9% decrease in the use of bevacizumab in these patients (not shown)

Adjuvant Therapy for Pancreatic Cancer:

Awareness and Importance of Abst. #LBA4006

OncoPoll_GI_Figure3

Key Conclusions

  • On the same 0 – 5 scale, treaters of pancreatic cancer are aware about this new clinical data, with level of awareness ranging between ~3.5-3.7
    • Much higher level of awareness among the attendees (3.8) compared to those who did not attend (2.9)
  • The addition of capecitabine to gemcitabine (GEMCAP) as an adjuvant therapy for pancreatic cancer is seen as very clinically important
    • Those outside of the US assign slightly more importance to this information, average rating of 4.0 vs. 3.8 for US respondents
    • With the higher level of awareness, more importance was seen by the attendees than with the non-attendees (not shown)
    • While these results will not have much impact on the overall use of adjuvant therapy in general, GEMCAP usage will experience a very large growth in usage and will be considered the standard of care in the adjuvant setting (not shown)

Conclusions: Immediate Impact of 2016 ASCO Presentations on Clinical Practice for mCRC and Pancreatic Cancers

  • Both of these studies highlight the importance of the ASCO Annual meeting to the entire global oncology community – awareness of these presentations are high and can occur quite quickly even for those who did not attend
  • Integration of these results into clinical practice are going to happen in relatively short order, especially since agents are already widely available and in use

For a more detailed analysis report, please click here to download the full report.

Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook

article register

Recent Posts

Recent Comments

Archives

Categories

Post a Comment

You must be logged in to post a comment